Return On Equity of Spyre Therapeutics, Inc. from 30 Sep 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Spyre Therapeutics, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Sep 2016 to 30 Sep 2025.
  • Spyre Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2025 was -31%, a 62% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Return On Equity for 2024 was -61%, a 111% decline from 2023.
  • Spyre Therapeutics, Inc. annual Return On Equity for 2023 was 576%.
  • Spyre Therapeutics, Inc. annual Return On Equity for 2022 was -127%, a 107% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Spyre Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 -31% +52% +62% 01 Jul 2025 30 Sep 2025
Q2 2025 -46% +114% +71% 01 Apr 2025 30 Jun 2025
Q1 2025 -49% -1300% -104% 01 Jan 2025 31 Mar 2025
Q4 2024 -61% -637% -111% 01 Oct 2024 31 Dec 2024
Q3 2024 -83% -402% -126% 01 Jul 2024 30 Sep 2024
Q2 2024 -160% -2112% -108% 01 Apr 2024 30 Jun 2024
Q1 2024 1251% +1383% 01 Jan 2024 31 Mar 2024
Q4 2023 576% +704% 01 Oct 2023 31 Dec 2023
Q3 2023 319% +434% 01 Jul 2023 30 Sep 2023
Q2 2023 1952% +2057% 01 Apr 2023 30 Jun 2023
Q1 2023 -132% -53% -68% 01 Jan 2023 31 Mar 2023
Q4 2022 -127% -66% -107% 01 Oct 2022 31 Dec 2022
Q3 2022 -115% -59% -105% 01 Jul 2022 30 Sep 2022
Q2 2022 -105% -55% -108% 01 Apr 2022 30 Jun 2022
Q1 2022 -79% -20% -35% 01 Jan 2022 31 Mar 2022
Q4 2021 -61% +7% +11% 01 Oct 2021 31 Dec 2021
Q3 2021 -56% +25% +31% 01 Jul 2021 30 Sep 2021
Q2 2021 -51% +49% +49% 01 Apr 2021 30 Jun 2021
Q1 2021 -58% +55% +49% 01 Jan 2021 31 Mar 2021
Q4 2020 -69% +19% +22% 01 Oct 2020 31 Dec 2020
Q3 2020 -81% -2% -3.2% 01 Jul 2020 30 Sep 2020
Q2 2020 -99% -28% -39% 01 Apr 2020 30 Jun 2020
Q1 2020 -113% -47% -70% 01 Jan 2020 31 Mar 2020
Q4 2019 -88% -17% -23% 01 Oct 2019 31 Dec 2019
Q3 2019 -79% -17% -27% 01 Jul 2019 30 Sep 2019
Q2 2019 -71% -14% -25% 01 Apr 2019 30 Jun 2019
Q1 2019 -67% -12% -21% 01 Jan 2019 31 Mar 2019
Q4 2018 -71% -23% -48% 01 Oct 2018 31 Dec 2018
Q3 2018 -62% -18% -41% 01 Jul 2018 30 Sep 2018
Q2 2018 -57% -18% -46% 01 Apr 2018 30 Jun 2018
Q1 2018 -55% -19% -54% 01 Jan 2018 31 Mar 2018
Q4 2017 -48% 0% +0.72% 01 Oct 2017 31 Dec 2017
Q3 2017 -44% +43% +49% 01 Jul 2017 30 Sep 2017
Q2 2017 -39% 01 Apr 2017 30 Jun 2017
Q1 2017 -36% 01 Jan 2017 31 Mar 2017
Q4 2016 -49% 01 Oct 2016 31 Dec 2016
Q3 2016 -87% 01 Jul 2016 30 Sep 2016

Spyre Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -61% -637% -111% 01 Jan 2024 31 Dec 2024
2023 576% +704% 01 Jan 2023 31 Dec 2023
2022 -127% -66% -107% 01 Jan 2022 31 Dec 2022
2021 -61% +7% +11% 01 Jan 2021 31 Dec 2021
2020 -69% +19% +22% 01 Jan 2020 31 Dec 2020
2019 -88% -17% -23% 01 Jan 2019 31 Dec 2019
2018 -71% -23% -48% 01 Jan 2018 31 Dec 2018
2017 -48% 0% +0.72% 01 Jan 2017 31 Dec 2017
2016 -49% 01 Jan 2016 31 Dec 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.